Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of IM19 CAR-T cells in relapsed or refractory CD19-positive acute B-lymphoblastic leukemia
CTR20220682Phase 2Active
- Sponsor
- Immunochina Pharmaceuticals
- Start
- May 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of IM19 Chimeric Antigen Receptor T Cell Injection in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Immunochina Pharmaceuticals. Started May 2022; status: active.
02
Drugs
IM19 Chimeric Antigen Receptor T Cell Injection
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on CTR20220682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220682.